Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography.
(18)F-fluoro-2-deoxyglucose positron emission tomography has demonstrated high accuracy in the staging and evaluation of colorectal and esophageal carcinomas. FDG PET is demonstrating increasing utility in a number of other gastrointestinal tumours and clinical scenarios. The established clinical indications for its use, the diagnostic accuracy, and limitations will be reviewed. Data on the emerging indications and limitations for pancreatic, hepatocellular, and gastric carcinomas, as well as gastrointestinal stromal tumours, cholangiocarcinoma, and carcinoma of unknown primary will also be briefly discussed. The use of combined PET-CT is demonstrating further improvements in diagnostic accuracy.
Chin
Bennett B
BB
Division of Nuclear Medicine, Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. chin0004@mc.duke.edu
Chang
Paul P L
PP
D002986:Clinical Trials as Topic; D019788:Fluorodeoxyglucose F18; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18